Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
As GLP-1 therapies expand beyond diabetes and obesity, understanding their anti-inflammatory mechanisms may unlock new therapeutic uses
The Phase 2 dose-finding trial (N=338), published in the New England Journal of Medicine in 2023 (DOI: 10.1056/NEJMoa2301972), randomized participants with obesity (BMI 30-50) to retatrutide at doses ranging from 0.5mg to 12mg weekly or placebo over 48 weeks
That all may change soon, at least for BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax
Such complications could turn deadly
Combination formulations that include GLP-1 medications with other weight management or diabetes medications in a single delivery system are also being explored
It also lowers the risk of major cardiovascular events such as stroke, heart attack, or death in adults with type 2 diabetes who also have heart disease, and lowers the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes who also have chronic kidney disease
US$ 23.73
US$ 24.62
US$ 27.61
US$ 26.46
US$ 25.47
